Additionally, basal and on-treatment serum levels of IL-6 were associated with clinical oncologic outcomes of patients with CSCC treated with cemiplimab, our study was not designed to demonstrate a causal role of IL-6. This evidence concerns the gene IL6 and skin squamous cell carcinoma.